Now that the US FDA's drugs and biologics centers have completed their rollout of the benefit-risk framework for new products and efficacy supplements, the agency is eyeing ways to incorporate the structured assessment into the advisory committee process.
The benefit-risk framework (BRF) could help frame questions for advisory committee discussion, the agency said in an updated draft implementation...








